RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Registration Number
- NCT05600218
- Lead Sponsor
- Hospital Costa del Sol
- Brief Summary
This is an observational, ambrispective study of patients in real world clinical practice, who has pulmonary arterial hypertension in whom a prostacyclin IP receptor agonist (Selexipag) is initiated between 2017 and 2021.
The aim of this study answer the following questions:
* Changes in the mortality risk profile of these patients after treatment administration.
* Baseline characteristics of patients initiating Selexipag.
* Parameters used for risk stratification prior to treatment escalation.
* Events during follow-up.
No comparison group available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
- They agree to participate in the study by signing an informed consent form
- Decline to participate in the study
- Patients living 6 months or less in the reference health area
- Patients with active malignant tumors
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cohort 1 No intervention - Observational study Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
- Primary Outcome Measures
Name Time Method Clinical improvement (risk profile) 12 months Percentage of patients reducing annual mortality risk profile according to ESC/ERS Clinical Practice Guidelines 2015 Risk Stratification.
- Secondary Outcome Measures
Name Time Method Events 12 months Incidence of events in follow-up: admission for worsening pulmonary hypertension; need for systemic prostacyclins; unscheduled admission for any cause; death related to pulmonary hypertension; death from any cause.
Risk stratification variables Basaline Percentage of clinical tests that have been used to include study treatment.
Trial Locations
- Locations (10)
Hospital San Juan de la Cruz
🇪🇸Úbeda, Jaén, Spain
Hospital Costa del Sol
🇪🇸Marbella, Málaga, Spain
Hospital Regional de Malaga
🇪🇸Málaga, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital de Poniente
🇪🇸El Ejido, Almería, Spain
Hospital Juan Ramón Jiménez
🇪🇸Huelva, Spain
Hospital Clinico Universitario San Cecilio
🇪🇸Granada, Spain
Hospital Universitario Virgen de la Victoria
🇪🇸Málaga, Spain
Hospital Universitario de Valme
🇪🇸Sevilla, Spain
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain